Institute of Basic and Translational Medicine, Shaanxi Key Laboratory of Brain Disorders, Xi'an Medical University, Xi'an, Shaanxi 710021, China; School of Basic and Medical Sciences, Xi'an Medical University, Xi'an, Shaanxi 710021, China.
The First Affiliated Hospital of Xi'an Medical University, Xi'an Medical University, Xi'an, Shaanxi 710077, China.
Biomed Pharmacother. 2022 Jul;151:113166. doi: 10.1016/j.biopha.2022.113166. Epub 2022 May 24.
The prevalence of liver disease has been increasing worldwide. Moreover, the burden of end-stage liver disease, including cirrhosis and liver cancer, is high because of high mortality and suboptimal treatment. The pathological process of liver disease includes steatosis, hepatocyte death, and fibrosis, which ultimately lead to cirrhosis and liver cancer. Clinical and preclinical evidence indicates that non-neoplastic liver diseases, particularly cirrhosis, are major risk factors for liver cancer, although the mechanism underlying this association remains unclear. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are transcriptional activators that regulate organ size and cancer development. YAP and TAZ play important roles in liver development, regeneration, and homeostasis. Abnormal YAP and TAZ levels have also been implicated in non-neoplastic liver diseases (e.g., non-alcoholic fatty liver disease, alcoholic liver disease, liver injury, and liver fibrosis). Here, we review recent findings on the roles of YAP and TAZ in non-neoplastic liver diseases and discuss directions for future research. This review provides a basis for the study of non-neoplastic liver diseases.
肝脏疾病的患病率在全球范围内呈上升趋势。此外，由于高死亡率和治疗效果不佳，终末期肝脏疾病（包括肝硬化和肝癌）的负担很重。肝脏疾病的病理过程包括脂肪变性、肝细胞死亡和纤维化，最终导致肝硬化和肝癌。临床和临床前证据表明，非肿瘤性肝脏疾病，特别是肝硬化，是肝癌的主要危险因素，尽管这种关联的机制尚不清楚。Yes 相关蛋白（YAP）和转录共激活因子与 PDZ 结合基序（TAZ）是调节器官大小和癌症发展的转录激活因子。YAP 和 TAZ 在肝脏发育、再生和稳态中发挥重要作用。异常的 YAP 和 TAZ 水平也与非肿瘤性肝脏疾病（如非酒精性脂肪性肝病、酒精性肝病、肝损伤和肝纤维化）有关。在这里，我们回顾了 YAP 和 TAZ 在非肿瘤性肝脏疾病中的作用的最新发现，并讨论了未来研究的方向。这篇综述为非肿瘤性肝脏疾病的研究提供了基础。
